Fig. 1: CRS Grade and Disease Response in Patients with Prophylactic Tocilizumab. | Blood Cancer Journal

Fig. 1: CRS Grade and Disease Response in Patients with Prophylactic Tocilizumab.

From: Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Fig. 1: CRS Grade and Disease Response in Patients with Prophylactic Tocilizumab.The alternative text for this image may have been generated using AI.

Myeloma response rate and CRS grade in 30 patients who received prophylactic tocilizumab. Of note, 8 Patients did not have an assessable response due to local follow-up or lack of time between data analysis and the last dose of teclistamab. These patients were not included in the total when calculating the response percentage.

Back to article page